2-(Piperidin-3-yl)-1H-benzo[d]imidazole

Catalog No.: 
ACJTIC351
CAS No.: 
123771-23-3
Molecular Formula: 
C12H15N3
Molecular Weight: 
201.27
2-(Piperidin-3-yl)-1H-benzo[d]imidazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g95%
25g95%
100g95%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(Piperidin-3-yl)-1H-benzo[d]imidazole
IUPAC Name2-(piperidin-3-yl)-1H-benzo[d]imidazole
MDL No.MFCD06738924
Molecular FormulaC12H15N3
Molecular Weight201.27
SMILESC1(C2CNCCC2)=NC3=CC=CC=C3N1
InChI KeyLQZIJJKVPOTLRE-UHFFFAOYSA-N
SynonymSCHEMBL740104 | CCG-210118 | SY081811 | UNII-S1976TE8QK | SR-01000024349 | 2-(3-piperidyl)benzimidazole | 2-(piperidin-3-yl)-1H-benzo[d]imidazole | CS-0035308 | 2-piperidin-3-yl-1H-benzimidazole | EN300-25964 | BB 0240353 | F2602-0247 | AKOS016040534 | 2-
CAS No.123771-23-3
PubChem CID5311916

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACJTIC351 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEJHQ928 route compound structure diagram
    ACEJHQ928498-95-3In Stock
  4. Then
  5. ACJTIC351 route product structure diagram
    ACJTIC351123771-23-3In Stock
Inquiry

2. ACJTIC351 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHLMI025 route compound structure diagram
    ACHLMI0251229000-10-5In Stock
  2. Then
  3. ACJTIC351 route product structure diagram
    ACJTIC351123771-23-3In Stock
Inquiry

3. ACJTIC351 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJTIC351 route product structure diagram
    ACJTIC351123771-23-3In Stock
Inquiry

Comments (0)